Race Oncology Produces First Batch of Bisantrene
Filed with ASX · · 3 pages · English
Earlier from Racura Oncology
- Appendix 4E & Annual Financial Statements
- Issue of Options
- Peer-Reviewed The Rediscovery of Bisantrene Published
- Race Completes Over-Subscribed $2.5 Million Placement
- Race Joint Venture with TargImmune
Later from Racura Oncology
- Race Receives $170k R&D Tax Incentive Refund
- Notice of Allowance for Bisantrene Patent in US
- Second Bisantrene Patent Allowed in US
- Race completes over-subscribed $3.159 million placement
- Race increases placement to $3.69m
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology